Connect with us

News

Ardigen Enters Into Research Collaboration With CVC to Apply Artificial Intelligence for Identification of T-cell Targets

Published

on

Ardigen and CVC announced that they entered a research collaboration aimed at the development of SARS-CoV-2 vaccine.

Ardigen’s neoantigen prediction platform called “ArdImmune Vax” employs state of the art bioinformatics and Artificial Intelligence to identify an optimal set of neoantigens as targets for cancer vaccines or adoptive cell therapies. This technology is also very well suited for the design of vaccines for infectious diseases. The core of the platform is a proprietary algorithm capable of predicting neoantigens’ probability to elicit an immune response. 

This joint research enables CVC to benefit from Ardigen’s vaccine design technology by selecting which viral epitopes are the most suitable to boost cellular immune response. Complementing humoral and cellular response in the vaccine design is expected to result in 2 strong lines of defense against the coronavirus. The approach is likely to be more effective than vaccines designed to create antibodies alone.

“We are thrilled to help global efforts to mitigate COVID-19 applying our breakthrough technology powered by Artificial Intelligence, reducing the vaccine design phase to a few weeks,” comments Janusz Homa, CEO of Ardigen.

Robert Feldman, CEO and Co-founder of CVC, adds: “CVC is excited to be working with Ardigen who are at the forefront of T-cell epitope design. The collaboration gives us the best chance of our product inducing an effective T-cell response against SARS-Cov-2.”

This News has been Published in Partnership with PR Newswire

Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Acquisition

Olympus announces acquisition of Arc Medical Design Limited from Norgine B.V.

Published

on

Olympus announces acquisition of Arc Medical Design Limited from Norgine B.V.

Olympus Corporation today announced it has signed a definitive agreement to acquire Arc Medical Design Limited (Arc Medical Design), a subsidiary of Norgine B.V. The acquisition underscores Olympus’ commitment to expanding its offering in gastrointestinal therapeutic devices and the development of advanced colonoscopy tools through M&A (mergers and acquisitions) opportunities as well as through R&D (research and development) with the overarching goal of improving early detection and treatment of colorectal cancer (CRC).  

Under the agreement Olympus will acquire Arc Medical Design and obtain full rights to its suite of innovative medical products. Olympus will convert its current exclusive distribution rights of ENDOCUFF VISION™ to a full acquisition of the ENDOCUFF family of products, which also includes ENDOCUFF™, ENDOCUFF GLIDE™ and ENTEROCUFF™, as well as WIDE-EYE™ POLYTRAP and several products currently in development.

By acquiring Arc Medical Design, Olympus is assuming worldwide responsibility for design, manufacturing, distribution and business strategy for the product portfolio with an immediate effect. It will further enable the company to improve clinical outcomes, reduce overall costs and enhance quality of life for patients.

“It is a great pleasure to announce our acquisition of Arc Medical Design”, said Mike Callaghan, Vice President/General Manager of Global GI EndoTherapy Business Unit at Olympus. “ENDOCUFF VISION has been a pivotal tool in our EndoTherapy portfolio, and we are delighted to expand our product portfolio to include the entire ENDOCUFF family.”

The flagship product ENDOCUFF VISION is a device attached to the distal end of a colonoscope, designed to maintain and maximize visibility during colonoscopy. Through its unique design, ENDOCUFF VISION can manipulate large folds, anchor the scope tip during loop reduction and stabilize during complex procedures, such as a polypectomy.

Data has shown a colonoscopy with ENDOCUFF technology can increase the adenoma detection rate (ADR) by up to 11% compared to a standard colonoscopy*1. Research shows that, for every 1% increase in ADR, there is a 3% decrease in CRC risk*2. Higher detection rates and more accurate diagnosis could, therefore, help reduce the number of deaths from preventable digestive cancers, such as CRC. CRC is a leading cause of cancer death for both men and women and screening is one of the powerful weapons against the disease. Colonoscopy is considered the beneficial method for detection and removal of hard-to-find adenomatous polyps.

Callaghan sums up: “We are excited about the acquisition of Arc Medical Design as it expands our expertise in innovative medical technology, strengthens our global leadership in endoscopy and reinforces the commitment to our purpose of making people’s lives healthier, safer and more fulfilling.”

Continue Reading

Investment

Reward-based Fundraising and Preselling Startup CrowdPouch raises Angel Round from Elina Investments

Published

on

CrowdPouch, a reward-based fundraising and preselling platform, has raised an angel round funding from Elina Investments Pvt. Ltd. The Bengaluru based technology startup will utilize the funds for product development, branding and team expansion.

The funding from Elina Investments comes at a time when the company has already supported over 100 fundraising and pre-selling campaigns on its platform within a year of its inception. Going forward, CrowdPouch aims at hosting thousands of campaigns that encourage filmmakers, artists, innovators and dreamers to come forward and work towards fulfilling their dreams.

Floated by Syed Safawi, corporate leader and technology investor, Elina Investments has funded several successful startups at an early stage, including GoMechanic, PadUp, Tarnea Technology, Senpiper Technology and Zefmo Media to name a few.

“CrowdPouch is more than business for me. It has been my life’s goal to encourage artists, innovators, and visionaries across sectors to pursue their passion,” said Vittal Ramakrishna, CEO and Founder of CrowdPouch. “India has an untapped market for fundraising and most are unaware of the merits of preselling. Through CrowdPouch, our vision is to create a niche fundraising ecosystem where all essential factors culminate seamlessly to build a nation of dreamers and achievers. Elina has stepped in at the right moment to help us scale our efforts.”

“We at Elina firmly believe in the power of technology platforms and Crowdpouch is catalysing the democratisation of such opportunities in a vast country like India. It is an opportune time to focus on preselling, as the nation answers the clarion call of Aatmanirbhar Bharat and going Vocal for Local,” said Divyendu Kumar, Director, Elina Investments. “CrowdPouch is a wonderful platform and Vittal with his team bring in the right blend of passion, maturity and understanding to be able to leverage the massive opportunity that it presents – both in scale and quality.”

Continue Reading

Artificial Intelligence

AIBotics Go-Digital Series 2020 Showcases AI and Robotic Innovations to Augment Human Potential

Published

on

SINGAPORE, Aug. 3, 2020 — Asia Pacific Assistive Robotics Association (APARA), a non-profit organization founded to facilitate adoption and augmentation of Artificial Intelligence (AI) and Robotics, today announced AIBotics Go-Digital Series 2020, an AI and Robotics event themed around ‘Augmenting the Human Potential’, will be launched between August and November 2020, aiming to facilitate the increasing dependency on AI technology into improving human lives.

An international event endorsed and supported by the International Alliance of Robotics Associations (IARA) and a number of global and regional partners including the University of Oxford, the ASEAN Smart Cities Network, Japan Science & Technology Agency, the Malaysian Artificial Intelligence and Robotics Association, among others, AIBotics Go-Digital Series 2020 reviews ethical and responsible AI and robotics innovations through webinars and a virtual exhibition 24 hours a day, seven days a week from August for four months, bringing together renowned industry experts as well as a number of projects and innovative solutions from all around the world.

To enable a smart, seamless and sustainable digital conferencing experience, APARA is collaborating with Tencent Cloud, the official conferencing solution provider of AIBotics Go-Digital Series 2020, to bring visitors and delegates a series of power-packed webinars and a virtual exhibition through Tencent Cloud Conference (TCC) solutions which have been widely adopted by local and overseas organizations and enterprises at online and digital business conferences, annual meetings, road shows, lectures, industry forums, among others.

“As we adjust to the ‘new normal’ brought about by the COVID-19 pandemic, AI has also become much more mainstream while allowing gatherings and business meetings to be held amid current circumstances. We are excited to present AIBotics Go-Digital Series 2020, highlighting how AI and Robotics can truly augment human potential, which is a timely message in light of the virus-related disruptions globally,” said Shanlynn Lee, President of APARA.

“One of the benefits of us going online this year is that unlike conventional conferences, we will be serving our visitors from all around the world for the whole duration of the event, without closing for business, with seamless digital conferencing support from Tencent Cloud. What’s more, visitors can simply register with AIBotics Go-Digital to have access to the webinars and the virtual exhibition, a marketplace that never sleeps, for four months, so they can take their time and come back again and again to see all the exhibits even after the event with no rush,” Ms. Lee added.

Featuring speakers from the UK, Finland, Germany, Israel, Japan, Malaysia, New Zealand and South Korea amongst many other countries, AIBotics Go-Digital Series 2020 aims to drive and showcase AI and Robotics applications across a variety of sectors, address issues in its development and offer recommendations for utilizing such applications with the protection of important human values in mind.

Continue Reading

Trending

Subscribe to our Free Newsletter

Get Business and Marketing Insights from Experts, only onTimes of Startups!

Your Information will never be shared with any third party